Stock ATXI AVENUE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Avenue Therapeutics, Inc.

Equities

ATXI

US05360L3042

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
0.117 USD +24.07% Intraday chart for Avenue Therapeutics, Inc. -98.84% -99.03%
Mar. 18 Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Feb. 22 Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy CI

Evolution of the average Target Price on Avenue Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

2ab45b0ba74.ir1314bC6BgxHR74HuoawkhggqH1_VRDOjabrvC3nhQ.0M0Dj9GNgk8GdHy8cLBtqyIizpKZxBsXVwP6woGP81Xf-TWivvqxUmhJeQ~fac67ca281e8118640f2438d855d4302

Analyst Recommendations on Avenue Therapeutics, Inc.

Maxim Starts Coverage on Avenue Therapeutics with Buy Rating, $0.75 Price Target MT
North American Morning Briefing : Stock Futures Dip as Higher Rate Fears Persist DJ
Wall Street Set to Open Lower as Mortgage Rates Climb to 16-Year High MT
US Futures Lower as Mortgage Rates Climb to 16-Year High MT
Avenue Therapeutics : Biotech incubator taps investors through in-house brokerage RE
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
8.775 USD
Average target price
1,228 USD
Spread / Average Target
+13,895.73%
High Price Target
2,400 USD
Spread / Highest target
+27,250.43%
Low Price Target
56.25 USD
Spread / Lowest Target
+541.03%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Avenue Therapeutics, Inc.

Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ATXI Stock
  4. Consensus Avenue Therapeutics, Inc.